Oruka Therapeutics, Inc.
Income Statement
| Line Item | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.0M | $4.7M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M |
| SG&A Expense | $6.3M | $5.8M | $5.5M | $4.8M | $4.0M | $3.9M | $4.6M | $4.3M |
| Operating Income | $-7.3M | $-10.6M | $-19.3M | $-9.8M | $-5.8M | $-8.1M | $-18.7M | $-16.6M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $9.0K | $7.0K | $8.0K | $6.0K | — |
| Pretax Income | — | — | $-19.3M | $-9.7M | $-5.6M | $-8.0M | $-18.6M | $-16.4M |
| Income Tax Expense | $0 | $0 | $0 | $-9.0K | $-167.0K | $-31.0K | $-61.0K | $0 |
| Net Income | $-5.3M | $-9.9M | $-19.3M | $-9.7M | $-5.5M | $-7.9M | $-18.5M | $-16.4M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.37 | $-0.69 | $-1.39 | $-2.07 | $-4.15 | $-10.31 | $-1.77 | $-1.81 |
| EPS (Diluted) | $-0.37 | $-0.69 | $-1.39 | $-2.07 | $-4.15 | $-10.31 | $-1.77 | $-1.81 |
| Shares Outstanding (Basic) | 14.4M | 14.4M | 13.9M | 9.5M | 1.6M | 773.6K | 11.8M | 9.1M |
| Shares Outstanding (Diluted) | 14.4M | 14.4M | 13.9M | 9.5M | 1.6M | 773.6K | 11.8M | 9.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |